COCRYSTAL PHARMA, INC. Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31)
COCRYSTAL PHARMA, INC. (COCP) had Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) of $2.00 million as of 2011-06-30, per its 10-K filed 2013-04-01.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue · last filed 2013-04-01
- 2011-06-30: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $2.00M.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2011-06-30 | $2.00M 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |